Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19

Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines was pleased to read an interesting Nature paper published online yesterday, highlighting the role of T-Cells in some COVID-19 patients, providing rapid clearance of SARS-CoV-2 and strong and long lasting immunological memory. The paper also received coverage in articles in The Guardian and The Times newspapers today.

These data provide evidence to support our approach to vaccine development. Our next generation vaccines are designed to deliver broad and long lasting immunity by triggering the body’s T-Cell response. T-Cell vaccine technology offers the potential for long-lasting immunity that does not require seasonal boosting and may be better suited to rapidly mutating viruses than where new variants are generated and antibodies may become less effective.

– Ends –

For further information, please contact:


Storme Moore-Thornicroft, Executive Director
Phone: +44 (0) 1235 527589

Robin Cohen, Chief Commercial Officer
Phone: +44 (0) 1235 527589

Consilium Strategic Communications
Chris Gardner / Ashley Tapp / Aaron Kelly
Phone: +44 (0)20 3709 5700

About Emergex

Emergex, a biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of synthetic vaccines which prime the T-Cell immune response to address some of the world’s most immediate health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.

These set-point vaccines modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease.

Emergex uses a synthetic nano gold carrier system to deliver a specific set of peptides to the body’s immune system, generating a robust T-Cell response that has the potential to provide a rapid and broad immune response that may last for decades.

The Company has a growing pipeline of vaccine candidates. The most advanced development programmes are a vaccine for Dengue Fever. The vaccine technology offers the potential for cross-reactive immune responses for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex has programmes in development for a universal Influenza vaccine, a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine, a therapeutic Hepatitis B vaccine and a Chikungunya vaccine.

Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease. The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.

Find out more online at